RxDoctor Payments Data

Nancy Hart

Psychiatric/Mental Health · Pensacola, FLNPI 1073536603

Payments from drug & device makers

$4,829in general payments, 2019–2025

Across 260 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$666
  • Teva Pharmaceuticals USA, Inc.$659
  • AbbVie$497
  • Otsuka America Pharmaceutical, Inc.$469
  • Johnson & Johnson$424
  • Alkermes, Inc.$353
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$4,829100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,829 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$13,733
Medicare patients
65
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl39$60,337
TrintellixVortioxetine Hydrobromide13$13,950
Aripiprazole129$11,364
Lurasidone Hcl11$6,228
Quetiapine Fumarate277$4,514
Atomoxetine Hcl28$3,970
Duloxetine Hcl89$2,690
Hydroxyzine Pamoate121$1,962
Divalproex Sodium75$1,894
Paliperidone ErPaliperidone15$1,786
Olanzapine69$1,748
Benztropine Mesylate87$1,592
Mirtazapine49$1,542
Buspirone Hcl99$1,520
Risperidone97$1,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$497$60,33739 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$63$13,95013 claims
Almatica Pharma LLCSertraline Hcl$35$61063 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →